To examine whether the tumor microenvironment alters cytokine-induced cytotoxicity, human prostate adenocarcinoma DU-145 cells were exposed to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and/or glucose deprivation, a common characteristic of the tumor microenvironment. TRAIL alone reduced cell survival in a dose-dependent manner. Glucose deprivation alone induced no cytotoxicity within 4 h. However, the combination of TRAIL (50 ng/ml) and glucose deprivation for 4 h increased cell death and PARP cleavage by promoting activation of caspase-8 and caspase-3, relative to that of TRAIL alone. Similar results were observed in human colorectal carcinoma CX-1 cells. Data from immunoblotting analysis reveal that glucose deprivation-enhanced TRAIL cytotoxicity is inversely related to the intracellular level of FLICE inhibitory protein (FLIP) but not that of death receptor 5 (DR5). Results from mass spectrometry show that glucose deprivation elevates ceramide. The elevation of ceramide may cause dephosphorylation of Akt and maintain dephosphorylation of Akt in the presence of TRAIL and then subsequently down-regulate the expression of FLIP. Taken together, the present studies suggest that glucose deprivation enhances TRAIL-induced cytotoxicity through the ceramide ± Akt ± FLIP pathway.
Introduction
TRAIL, a cytokine, is an apoptosis-inducing member of the tumor necrosis factor (TNF) gene family based on amino acid homology to TNF and Fas ligand (FasL) (Wiley et al., 1995; Pitti et al., 1996) . The apoptotic signal of TRAIL is transduced by binding to the death receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5), members of the TNF receptor superfamily. Both DR4 and DR5 contain a cytoplasmic death domain that is required for TRAIL receptor-induced apoptosis. TRAIL also binds to TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2), which act as decoy receptors by inhibiting TRAIL signaling (DegliEsposti et al., 1997a,b; Marsters et al., 1997; Pan et al., 1997a,b; Sheridan et al., 1997; Walczak et al., 1997) . Unlike DR4 and DR5, DcR1 does not have a cytoplasmic domain and DcR2 retains a cytoplasmic fragment containing a truncated form of the consensus death domain motif (Pan et al., 1997a) . TRAIL induces apoptosis in a wide variety of tumor cells, but does not cause toxicity to most normal cells. However, recent studies reveal that a polyhistidine-tagged TRAIL induces apoptosis in normal human hepatocytes in culture (Jo et al., 2000) . This is probably due to an aberrant con®rma-tion and subunit structure of TRAIL in the presence of low zinc content (Lawrence et al., 2001) . In contrast, native-sequence, non-tagged recombinant TRAIL, when produced under optimized zinc concentration, is markedly more active against tumor cells than the polyhistidine-tagged ligand, but has minimal toxicity toward human hepatocytes in vitro (Lawrence et al., 2001) . Moreover, preclinical studies in mice and primates have shown that administration of TRAIL can induce apoptosis in human tumors, but no cytotoxicity to normal organ or tissue was found (Walczak et al., 1999) . Dierential sensitivity between normal and tumor cells to TRAIL has been explained by the presence of a high concentration of the decoy receptors in normal cells (Gura, 1997; Ashkenazi and Dixit, 1999) . Recently, this hypothesis has been challenged based on the results showing poor correlations between DR4, DR5, and DcR1 expression and sensitivity to TRAIL-induced apoptosis in normal and cancerous breast cell lines (Keane et al., 1999) . This discrepancy indicates that other factors such as death inhibitors including FLICEinhibitory protein (FLIP) (Grith et al., 1998) , Fasassociated protein (FAP-1) (Sato et al., 1995) , and inhibitor of apoptosis (IAP) (Kothny-Wilkes et al., 1999) are also involved in the dierential sensitivity to TRAIL. Recent studies show that genotoxic agents such as chemotherapeutic agents and ionizing radiation sensitize TRAIL-induced cytotoxicity by decreasing intracellular levels of FLIP or increasing DR5 gene expression (Grith et al., 1998; Chinnaiyan et al., 2000) .
Recent studies revealed that the Fas-associated death domain (FADD) is required for TRAIL-induced apoptosis (Kischkel et al., 2000; Kuang et al., 2000; Sprick et al., 2000) . TRAIL triggers apoptosis by recruiting the apoptosis initiator procaspase-8 through the adaptor FADD (Bodmer et al., 2000; Kischkel et al., 2000) . Caspase-8 can directly activate downstream eector caspases including procaspase-3, -6, and -7 (Cohen, 1997) . Caspase-8 also cleaves Bid and triggers mitochondrial damage that in turn leads to cytochrome c release (Li et al., 1998; Luo et al., 1998; Schendel et al., 1999) . Cytochrome c in the cytoplasm binds to Apaf-1, which then permits recruitment of procaspase-9 (Li et al., 1997) . Caspase-9 cleaves and activates procaspase-3 (Slee et al., 1999) . Recently, we observed that TRAIL-induced caspase-3 activation and apoptosis are mediated through two dierent apoptotic pathways, mitochondria-dependent and -independent (Lee et al., 2001a) . TRAIL-induced cytotoxicity is not signi®cantly inhibited by Bcl-2 overexpression (Gazitt et al., 1999; Walczak et al., 2000; Lee et al., 2001a) . These results suggest that TRAIL-induced apoptosis is primarily dependent upon a mitochondria-independent pathway. However, there are also a number of reports which suggest that Bcl-2 can signi®cantly inhibit TRAIL cytotoxicity and that caspase 3, Bid and cytochrome c release are required for TRAIL-induced apoptosis Gong and Almasan, 2000; Munshi et al., 2001; Rokhlin et al., 2001; Thakkar et al., 2001) . Thus this discrepancy needs to be clari®ed.
It is well known that severe architectural and functional abnormalities are commonly observed in the capillary network that develops during tumor growth . These abnormalities cause insucient blood supply and development of a pathophysiological tumor micro-environment. The tumor micro-environment is characterized by low oxygen tensions (hypoxia) (Vaupel et al., 1991) , low glucose concentrations (Gullino, 1975) , high lactate concentrations (Schwickert et al., 1995; Walenta et al., 1997) , and low extracellular pH (Wike-Hooley et al., 1984) . These characteristic features, which occur transiently or chronically, can markedly aect the therapeutic response (Sartorelli, 1988; Mueller-Klieser et al., 1989) . It is, therefore, very important to determine whether the tumor micro-environment aects the biochemical functions of TRAIL, in order to maximize its ecacy in cancer therapy. We have previously reported that glucose deprivation elevates ceramide levels (Lee et al., 2001b) . Recent studies reveal that the elevation of ceramide content inhibits either phosphatidylinositol (PI) 3-kinase [PI(3)K] (Zundel and Giaccia, 1998) and/or activates ceramide-activated protein phosphatase (CAPP) (Salinas et al., 2000) . PI(3)K phosphorylates phosphoinositides at the 3'-position of the inositol ring, and its major lipid product is phosphatidylinositol 3,4,5-triphosphate (PIP 3 ) (Rameh and Cantley, 1999) . PIP 3 facilitates the recruitment of Akt to the plasma membrane through binding with the pleckstrin homology (PH) domain of Akt (Rameh and Cantley, 1999). Akt is activated by phosphoinositide-dependent kinase-1 (PDK1) through phosphorylation at threonine 308 and serine 473 (Alessi et al., 1997; Anderson et al., 1998) . PI(3)K activity is directly down-regulated by ceramide (Zundel and Giaccia, 1998) . The inhibition of PI(3)K results in preventing the translocation of Akt to the plasma membrane. Unlike PI(3)K, CAPP, which is a member of the 2A class of Ser/Thr protein phosphatases (PP2A) (Chalfant et al., 1999; Dobrowsky and Hannun, 1992) , inhibits Akt by promoting dephosphorylation of serine 473 (Schubert et al., 2000) . Panka et al. (2001) reported that the PI(3)K ± Akt pathway regulates the expression of FLIP, an antiapoptotic molecule. In this study, we hypothesized that glucose deprivation promotes TRAIL-induced cytotoxicity by promoting the activation of caspases through the ceramide ± Akt ± FLIP pathway. Our results reveal that glucose deprivation-enhanced apoptosis is indeed associated with the reduction of FLIP level and the ceramide ± Akt ± FLIP pathway may play an important role in the regulation of FLIP gene expression.
Results

Glucose deprivation enhanced TRAIL-induced apoptotic cell death in DU-145 cells
The eect of glucose deprivation on cell death in conjunction with TRAIL was assessed in human prostatic adenocarcinoma, DU-145 cell line. Figure  1a shows, in DU-145 cells, glucose deprivation alone caused a substantial time-dependent reduction in cell survival, which was determined by colony formation assay. On the basis of this result, glucose deprivation for 4 h was selected for subsequent studies due to its showing of sublethal toxicity. Cell survival was also examined to assess cytotoxicity after TRAIL treatment with or without glucose deprivation for 4 h by colony formation assay (Figure 1b) . TRAIL alone reduced the cell survival at a dose of 10 ± 100 ng/ml in a dosedependent manner. Interestingly, the survival curve became biphasic as the TRAIL dose was increased. These results indicate that the cytotoxicity eect of TRAIL saturates at approximately 100 ng/ml or approximately 5% of the cell population was resistant to TRAIL. The combination of TRAIL and glucose deprivation increased cell death compared to cells treated with TRAIL alone, demonstrating that the cytotoxicity was signi®cantly enhanced by the combined treatment (Figure 1b) . Similar results were observed by Trypan blue exclusion assay ( Figure 1c ). As shown in Figure 1c , cells were killed during incubation with TRAIL alone in a dose-dependent manner. For example, 35% of cells were killed at the dose of 50 ng/ml of TRAIL for 4 h exposure. Glucose deprivation signi®cantly enhanced TRAIL-induced cell death in DU-145 cells: more than 95% of cells were killed after 4 h incubation with TRAIL (50 ng/ml). These observations were consistent with morphological features (Figure 1d ). Cells undergoing apoptosis during treatment with TRAIL showed cell surface blebbing and formation of apoptotic bodies. Signi®-cant apoptotic changes were enhanced by 50 ng/ml TRAIL treatment combined with glucose deprivation. Additional studies were designed to determine whether the combination of TRAIL and glucose deprivation enhances poly (ADP-ribose) polymerase (PARP) cleavage, the hallmark feature of apoptosis, in DU-145 cells. Figure 2 shows that glucose deprivation alone failed to induce PARP cleavage. In contrast, TRAIL (10 ± 50 ng/ml) alone caused PARP cleavage. PARP (116 kDa) was cleaved yielding a characteristic 85 kDa fragment in the presence of TRAIL. The amount of cleavage was TRAIL concentration dependent. PARP cleavage was markedly enhanced when TRAIL and glucose deprivation were combined ( Figure 2 ). These results consistently show that glucose deprivation signi®cantly enhances TRAILinduced apoptosis. Similar results were observed in human colorectal carcinoma CX-1 cells ( Figure 3 ). As shown in Figure 3 , 44% of cells were killed by 3 h treatment with 200 ng/ml TRAIL alone. In contrast, more than 87% of cells were killed by 200 ng/ml TRAIL treatment in the absence of glucose. TRAILinduced PARP cleavage was also enhanced by TRAIL treatment combined with glucose deprivation in CX-1 cells ( Figure 3 ).
A combination of glucose deprivation and TRAIL treatment promotes the activation of caspases
It is well known that apoptosis induced by TRAIL is characterized by the activation of caspases (Mariani et al., 1997) . Thus, we further examined the eect of glucose deprivation on TRAIL-induced activation of caspases. In particular, the eect of TRAIL on caspase-8 (FLICE) and caspase-3 (CPP32) activation was assessed in the presence or absence of glucose in DU-145 cells (Figure 4 ). Cells were exposed to glucose free medium and/or various concentrations of TRAIL for 4 h. The activation of caspase-8 was detected by treatment with TRAIL alone. Procaspase-8 (55 kDa), the precursor form of caspase-8, was cleaved to the intermediate (43 and 41 kDa) and active forms (18 kDa). The combined treatment with TRAIL and glucose deprivation resulted in an increase in caspase-8 activation compared to TRAIL alone ( Figure 4) . Similar results were observed in the activation of caspase-3. TRAIL induced proteolytic processing of procaspase-3 into its signature forms (17 and 12 kDa). The activation of caspase-3 induced by TRAIL was enhanced in the absence of glucose (Figure 4) . These results demonstrated that glucose deprivation enhances TRAIL-induced apoptosis by promoting caspase activation in DU-145 cells. (D) Cells were treated with glucose-free medium alone (7Glu), 50 ng/ml TRAIL alone (TRAIL 50 ng/ml) or TRAIL in glucose-free medium (7Glu+TRAIL 50 ng/ml), and then morphological features were analysed with phase contrast microscopy. Con, untreated control cells Figure 2 Eect of glucose deprivation on TRAIL-induced proteolytic cleavage of PARP. DU-145 cells were treated with various concentrations (10 ± 50 ng/ml) of TRAIL for 4 h in the absence or presence of glucose and then harvested. Lysates containing equal amounts of protein (20 mg) were separated by SDS ± PAGE and immunoblotted. The upper band indicates 116 kDa PARP whereas the lower band indicates the 85 kDa apoptosis-related cleavage fragment. Con, untreated control cells. 7Glu, cells were treated with glucose-free medium alone. TRAIL, cells were treated with TRAIL alone. 7Glu+TRAIL, cells were treated with TRAIL in the absence of glucose. Actin was used to con®rm the equal amount of proteins loaded in each lane FLIP but not DR5 is decreased after combined treatment of TRAIL and glucose deprivation Previous studies show that genotoxic agents such as chemotherapeutic agents (Grith et al., 1998; Keane et al., 1999; Nagane et al., 2000) and ionizing radiation (Chinnaiyan et al., 2000) can sensitize TRAIL-induced cytotoxicity by decreasing intracellular levels of FLIP (Grith et al., 1998) or increasing DR5 gene expression in response to genotoxic stress (Sheikh et al., 1998; Chinnaiyan et al., 2000; Nagane et al., 2000) . To examine whether DR5 and FLIP are associated with the enhancement of apoptosis by TRAIL in combination with glucose deprivation, we examined DR5 and FLIP (long form and its spliced short form) level by Western blotting ( Figure 5 ). The DR5 level was not changed in DU-145 cells treated with TRAIL and/or glucose deprivation relative to untreated control cells ( Figure  5a ). Although FLIP levels in DU-145 cells exposed to either TRAIL or glucose deprivation were unchanged, combined treatment of glucose deprivation and TRAIL resulted in a decrease in both FLIP L and FLIP g levels within 4 h when compared with the TRAIL or glucose deprivation alone (Figure 5b ). These data demonstrate that reduction of FLIP levels by glucose deprivation in combination with TRAIL correlates with an increase in apoptosis in DU-145 cells. Glucose deprivation in combination with TRAIL may disrupt the PI(3)K pathway and subsequently reduce Akt phosphorylation (inactivation of Akt) and consequently down-regulate FLIP gene expression. To examine this possibility, DU-145 cells were treated with TRAIL (50 ng/ml) and/or glucose deprivation for 15 ± 120 min. Figure 6 shows that glucose deprivation transiently dephosphorylated Akt at serine 473 (S473). Combined glucose deprivation and TRAIL treatment sustained dephosphorylation of Akt. However, TRAIL alone did not alter phosphorylation of Akt. Our results (Figures 5 and 6 ) and a previous report (Panka et al., 2001) indicate that glucose deprivation in combination with TRAIL treatment eectively dephosphorylates the S473 residue of Akt and results in inactivation of Akt and subsequently down-regulates FLIP expression.
Ceramide enhances TRAIL-induced cytotoxicity through reduction of FLIP expression level by inhibiting Akt activity
Recent studies have shown that ceramide inhibits either PI(3)K (Zundel and Giaccia, 1998) Figure 4 Activation of caspases following treatment with combination of glucose deprivation and TRAIL. DU-145 cells were treated with TRAIL (10 ± 50 ng/ml) and/or glucose deprivation for 4 h and then lysed. Lysates were subjected to immunoblotting for caspase-8 and caspase-3. Antibody against caspase-8 detects inactive form (55 kDa), cleaved intermediates (43 kDa and 41 kDa), and active subunit (18 kDa). Anti-caspase-3 antibody detects both inactive form (32 kDa) and active form (17 kDa and 12 kDa). Con, untreated control cells. 7Glu, cells were treated with glucose-free medium alone. TRAIL, cells were treated with TRAIL alone. 7Glu+TRAIL, cells were treated with TRAIL in the absence of glucose. Actin, internal standard actin protein subsequently inhibits Akt by promoting dephosphorylation of serine 473 (Schubert et al., 2000) . We examined whether glucose deprivation increases the level of ceramide in DU-145 cells. Figure 7 shows that glucose deprivation for 0.5 h induced 3.8-, 1.5-and 2.2-fold increases in C16 : 0, C24 : 0 and C24 : 1 ceramides, respectively. To investigate the eect of ceramide on the TRAIL-induced cytotoxicity, cells were treated with ceramide (25 ± 100 mM) in combination with TRAIL (50 ng/ml) for 4 h. Ceramide alone caused a substantial dose-dependent reduction in cell survival. The combination of TRAIL and ceramide increased cell death, compared to cells treated with TRAIL alone (Figure  8a ). Figure 8b shows that ceramide alone failed to induce PARP cleavage. However, when TRAIL (50 ng/ml) and ceramide (25 ± 50 mM) were combined, PARP cleavage was markedly enhanced (Figure 8b ). These results consistently show that ceramide signi®cantly enhances TRAIL-induced apoptosis. We further examined whether Akt activity can be inactivated by treatment with ceramide (25 ± 50 mM) and/or TRAIL (50 ng/ml). Reduction of Akt phosphorylation at Ser-473 was observed in cells treated with ceramide alone or both ceramide and TRAIL (Figure 8c) . To con®rm the involvement of Akt in FLIP expression, FLIP level was determined by Western blot analysis. The FLIP L level was decreased during treatment with ceramide in the presence or absence of TRAIL (Figure 8c ). These data indicate that glucose deprivation-generated ceramide enhances TRAIL-induced apoptosis by inhibiting Akt and subsequently down-regulating FLIP expression.
Schematic diagram of apoptosis pathway induced by TRAIL and glucose deprivation
Our experimental data are summarized in Figure 9 . Our data indicate that glucose deprivation promotes ceramide generation. The elevation of ceramide may activate CAPP or inactivate PI(3)K. The activated CAPP and/or PI(3)K probably dephosphorylates Akt and dephosphorylation of Akt is sustained by treatment with TRAIL. The dephosphorylation (inactivation) of Akt subsequently results in down-regulation of FLIP. Reduction of intracellular levels of FLIP may be responsible for promoting caspase activation during TRAIL treatment.
Discussion
TRAIL is a member of the TNF family and activates apoptosis in various tumor cell lines (Wiley et al., 1995; Pitti et al., 1996) . Recent studies reveal that interferons activate caspases and the mitochondrial-dependent apoptotic pathway, possibly mediated by TRAIL production . Several researchers have also shown that chemotherapeutic agents (Grith et al., 1998; Keane et al., 1999; Nagane et al., 2000) and ionizing radiation (Chinnaiyan et al., 2000) can sensitize TRAIL-induced cytotoxicity. The synergistic eect may result from a decrease in intracellular levels of FLIP, a death inhibitor (Grith et al., 1998) or an increase in DR5 gene expression in response to genotoxic stress (Sheikh et al., 1998; Chinnaiyan et al., 2000; Nagane et al., 2000) . Our results from Figure  5 show that glucose deprivation-enhanced TRAIL cytotoxicity is not related with DR5 level. Rather, it is correlated with a decrease in intracellular concentrations of FLIP. These results indicate that not only dierential expression levels of TRAIL receptors, but also those of death inhibitors such as FLIP are responsible for TRAIL sensitivity.
As shown in Figure 1b , the survival curve became biphasic as the TRAIL concentrations were increased. The biphasic survival curve indicates either the Figure 6 Eect of glucose deprivation and/or TRAIL on Akt S473 phosphorylation in DU-145 cells. Cells were treated with 50 ng/ml TRAIL in the presence or absence of glucose for various time intervals (15 ± 120 min). Lysates containing equal amounts of protein (20 mg) were separated by SDS ± PAGE and immunoblotted with anti-Akt antibody or anti-phospho-S473 Akt antibody. Con, Untreated control cells. TRAIL, cells were treated with 50 ng/ml TRAIL alone 7Glu+TRAIL, cells were treated with 50 ng/ml TRAIL in the absence of glucose. P, a positive control sample from insulin treated tissue presence of two dierent populations (TRAIL resistant or sensitive) or the development of resistance during TRAIL treatment. When survived cells were harvested and grown for several generations, they were still sensitive to TRAIL (unpublished data). However, when cells were pretreated with TRAIL, they became resistant to a second TRAIL exposure within a short period. The resistance was developed, reached its maximum within 8 h, and decayed after 24 h to a second TRAIL treatment (unpublished data). These results suggest that the biphasic survival curve was due to the development of TRAIL resistance rather than selection of a TRAIL resistant population during TRAIL treatment.
In this study, we observed that down-regulation of FLIP gene expression might be related with enhanced Figure 7 Negative electrospray ionization-mass spectrometry of DU-145 whole cell lipid extracts identi®es multiple lipid species. Cells were exposed to glucose-free medium for 0.5 h and then extracted as described in Materials and methods. 1610 6 cell equivalents were injected into the mass spectrometer, and spectra were summed for 1 min over the mass range of 400 ± 950 Da/e. (A) control cells; (B) glucose-deprived cells. (a) The C16 ceramide runs at a m/z (mass to change) of 572.5 (chloride adduct); (b) the C24 : 0 runs at 684.6; and (c) the C24 : 1 runs at 682.6 (both as chloride adducts) apoptotic cell death by combination of glucose deprivation and TRAIL. Unlike genotoxic agents, glucose deprivation does not up-regulate DR5 transcription in DU-145 cells. Recent studies demonstrated that intracellular concentrations of FLIP which decreased rapidly after treatment with cycloheximide are correlated with an increase in TRAIL sensitivity and activation of caspase-8 in primary keratinocytes (Leverkus et al., 2000) . In addition, overexpression of FLIP is also known to suppress FasL and TNF-ainduced apoptosis (Irmier et al., 1997; Thome et al., 1997) . A fundamental question which remains unanswered is how TRAIL in combination with glucose deprivation reduces the intracellular level of FLIP. At the present time, we can only speculate the mechanism of down-regulation of FLIP during combined treatment of glucose deprivation and TRAIL. Previous studies (Liu and Hannun, 1997) have demonstrated that at physiological concentrations, glutathione (GSH) inhibits neutral Mg 2+ -dependent sphingomyelinase (SMase). During glucose deprivation, an increase in glutathione disul®de (GSSG) content may lead to the activation of SMase. It is well known that the activation of SMase causes the hydrolysis of sphingomyelin and results in the generation of ceramide (Okazaki et al., 1989) . The elevation of ceramide content may subsequently inactivate PI(3)K (Zundel and Giaccia, 1998) and/or activate CAPP which is a member of the 2A class of Ser/Thr protein phosphatases (PP2A) and protein phosphatase-1 (PP1) (Dobrowsky and Hannun, 1992; Chalfant et al., 1999) . The inactivated PI(3)K and/or CAPP probably dephosphorylates Akt and subsequently down-regulates FLIP gene expression (Panka et al., 2001) . However, recent studies reveal that ceramide inhibits Akt activity directly without aecting PI(3)K activity . Glucose deprivation-generated ceramide may directly aect Akt activity. This possibility needs to be investigated further. Nonetheless, results from our studies demonstrate that the glucose deprivation ± ceramide ± Akt ± FLIP pathway may play an important role in glucose deprivation-enhanced TRAIL cytotoxicity. However, we shall not rule out any other possibilities. Recent studies have demonstrated that ceramide induces cytochrome c release from the mitochondria through cleavage of Bid followed by Figure 9 A model for the mechanism of TRAIL and glucose deprivation-induced apoptotic pathways translocation of truncated Bid into the mitochondria (Ghafourifar et al., 1999; Li et al., 1998) . This possibility needs to be examined further. Another possibility is that AMP-activated protein kinase (AMPK) is involved in the regulation of FLIP gene expression. Previous studies have shown that AMPK can be activated in response to glucose deprivation (Hayashi et al., 2000) . AMPK which is a metabolic sensor can be activated by increases in the AMP : ATP ratio. AMPK is known to phosphorylate many target proteins including Raf-1 and glycogen synthase (Hardie et al., 1998; Sprenkle et al., 1997) , and also regulate a number of gene expressions (Hardie et al., 1998) . AMPK may be involved in the down-regulation of FLIP in the presence of TRAIL. This possibility needs to be further investigated. Although we are far from understanding how glucose deprivation enhances TRAIL-induced cytotoxicity in DU-145 cells, in this study, however, we present the possible involvement of the glucose deprivation ± ceramide ± Akt ± FLIP pathway in the mechanism of glucose deprivation-enhanced TRAIL cytotoxicity. We believe that this model will provide a framework for future studies.
Materials and methods
Reagents and antibodies
Polyclonal anti-caspase-3 antibody was purchased from Santa Cruz (Santa Cruz, CA, USA). Anti-DR5 from Stressgen (Victoria, BC, Canada), anti-FLIP from Calbiochem (Darmstadt, Germany), and anti-phospho-Ser-473 Akt and anti-Akt from New England Biolabs (Beverly, MA, USA) were used. Monoclonal antibodies were purchased from the following companies: anti-caspase-8 from Upstate Biotechnology (Lake Placid, NY, USA), and anti-PARP from Biomol Research Laboratory (Plymouth Meeting, PA, USA). Other chemicals were purchased from Sigma (St. Louis, MO, USA).
Production of recombinant TRAIL
A human TRAIL cDNA fragment (amino acids 114 ± 281) obtained by RT ± PCR was cloned into a pET ± 23d (Novagen, Madison, WI, USA) plasmid, and expressed protein was puri®ed using the Ni-NTA His-Bind Resin Super¯ow according to the manufacturer's instructions (Novagen).
Cell culture and survival determination
Human prostate adenocarcinoma DU-145 cells or human colorectal carcinoma CX-1 cells were cultured in DMEM medium or RPMI medium, respectively, with 10% fetal bovine serum (HyClone) and 26 mM sodium bicarbonate for monolayer cell culture. The dishes containing cells were kept in a 378C humidi®ed incubator with a mixture of 95% air and 5% CO 2 . Two days prior to the experiment, cells were plated into 60-mm dishes. For survival determination, cells were trypsinized, counted, and plated at various densities of cells. After 10 ± 14 days of incubation, colonies were washed and stained with crystal violet. Colonies which contained more than 50 cells were counted as survivors. Data were normalized to untreated control plating eciencies. For Trypan blue exclusion assay (Burow et al., 1998) , trypsinized cells were pelleted and resuspended in 0.2 ml of medium, 0.5 ml of 0.4% Trypan blue solution and 0.3 ml of phosphate-buered saline solution (PBS). The samples were mixed thoroughly, incubated at room temperature for 15 min and examined.
Treatment with glucose deprivation and TRAIL Cells were rinsed three times with PBS solution which took approximately 15 min. Cells were treated with glucose-free DMEM medium with 10% dialyzed fetal bovine serum (Gibco BRL, Grand Island, NY, USA). For TRAIL treatment, cells were replaced with fresh medium containing TRAIL (10 ± 200 ng/ml).
Morphological evaluation
Approximately 5610 5 cells were plated into 60-mm dishes overnight. Cells were treated with TRAIL or glucose deprivation and then analysed by phase contrast microscopy for signs of apoptosis (Mac-Farlane et al., 1997) .
Protein extracts and polyacrylamide gel electrophoresis (PAGE)
Cells were lysed with 16Laemmli lysis buer (2.4 M glycerol, 0.14 M Tris, pH 6.8, 0.21 M sodium dodecyl sulfate, 0.3 mM bromophenol blue) and boiled for 10 min. Protein content was measured with BCA Protein Assay Reagent (Pierce, Rockford, IL, USA). The samples are diluted with 16lysis buer containing 1.28 M b-mercaptoethanol, and equal amount of protein was loaded on 8 ± 12% SDS-polyacrylamide gels. SDS ± PAGE analysis was performed according to Laemmli (1970) using a Hoefer gel apparatus.
Immunoblot analysis
Proteins were separated by SDS ± PAGE and electrophoretically transferred to nitrocellulose membrane. The nitrocellulose membrane was blocked with 7.5% nonfat dry milk in PBS-Tween-20 (0.1%, v/v) at 48C overnight. The membrane was incubated with anti-PARP, anticaspase-8, anti-caspase-3, anti-DR5, anti-FLIP, anti-phospho-Akt, or anti-Akt antibody (diluted according to the manufacturer's instructions) for 1 h. Horseradish peroxidase conjugated anti-rabbit or anti-mouse IgG was used as the secondary antibody. Immunoreactive protein was visualized by the chemiluminescence protocol (ECL, Amersham).
Extraction of cellular lipids
Cells were washed three times in PBS, the supernatant was removed and cells were resuspended in methanol (0.5 ml) containing butylated hydroxytoluene (BHT, 0.1 mg, Sigma). 1 ml of chloroform was added, and the mixture was vortexed and kept on ice, under a nitrogen atmosphere, for 1 h in the dark. Three hundred microliters ml of 0.15 M NaCl was added, and the chloroform layer was separated by centrifugation and dried under a stream of nitrogen. Extracts were dissolved in chloroform/methanol (1 : 2) prior to analysis by mass spectrometry.
Mass spectrometry
Lipids were analysed by direct infusion into a Quattro II triple quadrupole mass spectrometer (Micromass, Manchester, UK) using a sheath¯ow of 5 ml/min consisting of chloroform/methanol (1 : 2, v/v). Sample injection was 1610 6 cell equivalents and was infused via a 75 mm inside diameter capillary using a Beckman pump. The electrospray probe was operated at a voltage dierential of 73.1 keV (negative ion mode) or 3.5 keV (positive ion mode). Mass spectra were obtained by scanning the range of 400 ± 950 m/z every 1.6 s and summing individual spectra. Source temperature was maintained at 708C. Collision-induced dissociation spectra were obtained by selecting the (M-H)-ion of interest and performing daughter ion scanning in Q3 at 500 atomic mass unit/s using 3 millitorr argon in the collision chamber. The spectrometer was operated at unit resolution. Ceramide levels were quantitated as previously described (Thomas et al., 1999) .
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